A trial of AsiDNA monotherapy via systemic administration
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs AsiDNA (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Onxeo SA
- 25 Jan 2018 According to an Onxeo SA media release, with the first patients treated in a dose-escalation phase 1 study expected in the first quarter of 2018.
- 05 Jul 2017 According to an Onxeo SA media release, the company intends to file the phase I trial submission dossier to regulatory authorities by the end of 2017.
- 26 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 1 Dec 2017, according to an Onxeo SA media release.